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Summary
To examine the serum triglyceride (TG)-lowering effect of a soluble hesperidin derivative, glucosyl hesperidin (G-hesperidin), and its mechanisms , we carried out a G-hes peridin administration test in hypertriglyceridemic subjects. G-Hesperidin was administered to the subjects at 500mg/d for 24wk. In this study, the subjects were classified into high TG type (TG>150mg/dL), borderline-TG type (TG110-150mg/dL) and normal-TG type (TG<110mg/dL) on the basis of their initial serum TG values. Among these phenotypes, serum TG level significantly decreased in the high-TG type during the G-hesperidin admin istration period. It was also observed that elevated values of serum remnant-like particle cholesterol (RLP-C), apolipoprotein (apo) B, apo C-II, apo C-III and apo E occurred in the high-TG type and that these serum levels were significantly reduced by G-hesperidin admin istration. Moreover, polyacrylamide gel electrophoresis analysis of serum lipoproteins revealed that the very low-density lipoprotein (VLDL)/low-density lipoprotein (LDL) ratio and LDL migration index of the high-TG type were remarkably higher than those of the other phenotypes but that their high values were significantly reduced by the administra tion. These results indicate that G-hesperidin preferentially lowers serum TG in hypertriglyc eridemic subjects and that this effect is possibly caused by the improvement of VLDL metabolic abnormality, leading to the reduction of small dense LDL.
Key Words glucosyl hesperidin, hypertriglyceridemia, triglyceride, very low-density lipo protein, small dense LDL Hesperidin, which is a flavonoid compound abun dantly occurring in citrus fruit peel, is well known to decrease capillary fragility and permeability (1) . In addition, this material has been reported to have diverse physiological activities including antioxidant effect (1), antihypertensive effect (2) and antiallergic effect (3) . Therefore, hesperidin has attracted attention as a multi functional food ingredient. However, the use of this fla vonoid in the field of foods has been limited because of its low water solubility.
Hijiya and Miyake (4) have synthesized a soluble derivative of hesperidin, glucosyl hesperidin (G-hesperi din), by regioselective transglycosylation with cyclodex trin glucanotransferase from Bacillus stearothermophilus (Fig. 1) . G-Hesperidin is very soluble in water, and its solubility is about 10,000 times greater than that of conventional hesperidin (4) . Moreover, it has been veri fied that this derivative releases hesperidin through * To whom correspondence should be addressed .
E-mail; hmitsu@hayashibara.co.jp hydrolysis by brush border a-glucosidases (4, 5) . Our recent studies have shown that G-hesperidin as well as hesperidin exhibits such physiological activities as decrease of serum lipid peroxide level in hyperlipidemic mice (6) , antihypertensive effect on spontaneously hypertensive rats ( 7, 8) and suppression of passive cuta neous anaphylaxis in rats (9) . These findings indicate that G-hesperidin behaves as hesperidin in the body and results in the exhibition of physiological activities. Thus, G-hesperidin is considered to be available effectively as a hesperidin source.
Furthermore, we have found that the supplementa tion of G-hesperidin markedly lowers serum triglyceride (TG) in mice with hyperlipidemia induced by a high-fat diet (6) . Such a TG-lowering effect has been also observed in humans; it has been confirmed that 6-wk administration of G-hesperidin preferentially lowers serum TG level in hypertriglyceridemic subjects and that this effect is dependent on the dose level and term of G-hesperidin administration (10) . It has been demon strated that an elevated serum TG level is closely associ ated with the development of coronary artery disease and this association is attributed to the formation of small dense low-density lipoprotein (LDL), which has a smaller particle size than normal LDL (11) (12) (13) (14) (15) (16) (17) . We have also observed that G-hesperidin administration may contribute to the suppression of small dense LDL formation as well as the decrease of serum TG level (10) , suggesting a possibility that this flavonoid deriva tive exhibits a preventive effect against atherosclerosis progression.
In the present study, in order to further understand the effect of G-hesperidin on serum TG and lipoprotein profiles, we carried out a 24-wk administration test of G-hesperidin in hypertriglyceridemic subjects and ana lyzed the changes in serum lipid parameters.
MATERIALS
AND METHODS
1. Test substances. Tablets consisting of G-hesperi din (250mg), maltose (750mg) and sucrose stearate (30mg) were prepared and used for this study. G-Hes peridin was provided by Toyo Sugar Refining Co., Ltd. (Tokyo, Japan). Maltose was obtained from Hayashibara Biochemical Laboratories, Inc. (Okayama, Japan). Sucrose stearate was purchased from Mitsubishi Kagaku Foods Corp. (Tokyo, Japan).
2. Subjects. Adult male volunteers, who had a last ing serum TG level of at least 110mg/dL and were not receiving any lipid-lowering drugs, were recruited, and 25 men (26-65y old) were enrolled in this study. The purpose and prospect of the study were fully explained to each volunteer. All subjects gave their informed con sent before admission. This study was approved by the Ethics Committee of Hayashibara Biochemical Labora tories, Inc., and conducted in accordance with the Hel sinki Declaration of 1975 as revised in 1983.
3. Experimental protocol. After a 4-wk non-treat ment baseline period, all subjects received two tablets containing 250 mg of G-hesperidin at each bedtime (500mg/d G-hesperidin). These tablets were adminis tered for 24wk, followed by a 4-wk washout period. To examine serum parameters, blood sampling was per formed at the beginning of the baseline period (week 4), at the beginning of administration (week 0), at 5. Analysis of serum lipoprotein composition and evalua tion of LDL particle size. Serum lipoproteins were frac tionated by polyacrylamide gel electrophoresis (PAGE) using the LipoPhor system (Jokoh Co., Ltd., Tokyo, Japan) as described by . Briefly, fresh serum was electrophoresed on polyacrylamide gel containing Sudan Black B and then the gel was scanned with a densitometer. Figure 2 shows typical pattern of PAGE densitograph. From the PAGE pattern thus obtained, the ratio of the peak height of very low density lipoprotein (VLDL) fraction to one of LDL frac tion was calculated (VLDL/LDL ratio). The change in serum lipoprotein composition was analyzed based on the VLDL/LDL ratio. Moreover, the distance between the peaks of VLDL and LDL fractions and the distance between the peaks of VLDL and HDL fractions were measured on the PAGE pattern, and the relative migra tion index of LDL fraction (LDL-MI) was calculated by the following formula:
LDL-MI=(the distance between the peaks of VLDL and LDL fractions)/(the distance between the peaks of VLDL and HDL fractions) This value is correlated with LDL particle size (23) (24) (25) (26) . That is to say, the increase of LDL-MI indicates the decrease of LDL particle size. In particular, when the value is more than 0.3 5, the presence of small dense LDL is speculated (26) .
6. Classification of subjects according to hypertriglyceri demia phenotypes and efficacy analyses in each pheno type. In each serum parameter analyses, the mean of the two measurements obtained during the baseline period (the mean of week -4 and week 0 values) was regarded as the initial value. Based on the initial serum TG value thus obtained, all subjects were classified into the following 3 phenotypes: high-TG type (TG>150 mg/dL), borderline-TG type (TG 110-150mg/dL) and normal-TG type (TG<110mg/dL). The criteria for the phenotype classification were determined according to the descriptions of Al and Tanaka (27) and Vigna et al. (28) . To assess the efficacies of G-hesperidin, the changes of the initial values in serum parameters were analyzed in each phenotype at week 4, 8, 12, 16, 20, 24 and 28. Additionally, the changes of the initial val ues in VLDL/LDL ratio and LDL-MI were analyzed in the individual phenotypes at week 12, 24 and 28. of the subjects throughout the study. There was no change in body weight or body mass index in any phe notype during the study. Furthermore, there were no changes in serum creatinine or uric acid levels in any phenotype during the administration period. No clinical signs related to the treatment were observed in any phe notype.
Change in serum TG level
In the individual phenotypes mentioned above, we analyzed the changes in serum TG level after G-hesperi din administration. The result is shown in Fig. 3 .
No obvious changes in serum TG level were observed in the borderline-TG or normal-TG types during the study. 
Changes in serum apolipoprotein levels
In each phenotype, we also investigated whether the serum levels of 5 apolipoproteins (apo A-I, B, C-II, C-III and E), which are correlated with serum lipids, were Changes in serum TC, LDL-C and HDL-C levels of respective phenotypes. No differences were seen in the initial serum apo A-I value among the 3 phenotypes. Moreover, this serum level showed no obvious change in any phenotype dur ing the administration period.
The initial serum apo B, C-II, C-III and E values tended to be elevated in the high-TG type, compared to those of the borderline-TG and normal-TG types. Ele vated values of these apolipoproteins significantly decreased in the high-TG type during the administra tion period; particularly, they were markedly reduced in the latter half of the period. These effects had a ten dency to disappear 4wk after the cessation of adminis tration. In addition, similar effects were also observed in the borderline-TG type subjects, but they failed to be observed in the normal-TG type.
Change in serum lipoprotein composition
In the individual phenotypes, the changes in serum lipoprotein composition after G-hesperidin administra tion were analyzed on the basis of the VLDL/LDL ratio, which was calculated on the PAGE pattern of serum lipoproteins. The result is shown in Fig. 7 . Additionally, typical PAGE patterns obtained in this analysis are shown in Fig. 8 .
The initial VLDL/LDL ratio of the high-TG type was higher than those of the borderline-TG and normal-TG tration. The experiment was performed as described in Fig. 7 , and serum obtained at the indicated time point was sub jected to PAGE using the LipoPhor system. LDL-MI was calculated on each PAGE pattern. These observations suggest that in the subjects with a high serum TG level their hepatic functions are improved by G-hesperidin administration. 8. Change in LDL particle size
In respective phenotypes, we further analyzed the changes in LDL particle size on the basis of the LDL-MI, which was calculated on the PAGE pattern of serum lipoproteins. The result is shown in Fig. 10 (see Fig. 8 about typical PAGE patterns). The initial LDL-MI of the high-TG type tended to be higher than those of the borderline-TG and normal-TG types, and the value was more than 0.35. From this observation, the LDL particle size of the high TG type was suggested to be smaller than those of the other phe notypes. Additionally, it was speculated that the high TG type might possess small dense LDL.
The LDL-MI of the normal-TG type was unchanged throughout the study and remained within the normal range (<0.35).
In contrast, the LDL-MI of the high-TG type was sig nificantly reduced during the administration period, indicating an expansion of LDL particle size. This effect disappeared 4wk after the cessation of administration.
Furthermore, a similar effect was also recognized in the borderline-TG type, although it was moderate as com pared with the effect obtained in the high-TG type.
These results indicate that the subjects with a high serum TG level, especially the high-TG type subjects, are led to the reduction of small dense LDL formation by G hesperidin administration.
DISCUSSION
Our previous study has shown that G-hesperidin preferentially lowers serum TG level in hypertriglyceri demic subjects and may contribute to the suppression of small dense LDL formation (10) . In the present study, to gain a better understanding of these effects by G-hes peridin and their mechanisms, we examined whether 24-wk administration of G-hesperidin affects serrrrum lipid parameters in subjects whose serum TG level is more than 110mg/dL.
As shown in Table 1 , the study subjects were classi fied into high-TG type (TG>150mg/dL), borderline-TG type (TG 110-150mg/dL) and normal-TG type (TG <110mg/dL). Among these phenotypes, serum TG level showed a significant reduction in the high-TG type during the administration period (Fig. 3) . This result agreed well with that obtained by the 6-wk administra tion test of G-hesperidin, which was conducted in our previous study (10) . From these observations, there fore, it was reconfirmed that G-hesperidin is effective in cases of elevated serum TG level.
Hypertriglyceridemia is known to be attributed to the accumulation of serum TG-rich lipoproteins such as VLDL and its metabolites, remnant lipoproteins (30 32) . In addition, it is considered that the accumulation of these TG-rich lipoproteins in serum is caused by an unbalance of the synthesis and catabolism of VLDL, namely, VLDL metabolic abnormality (30) (31) (32) . In the present test, it was observed that the initial serum RLP C value of the high-TG type was markedly elevated in comparison with those of the other phenotypes (Fig. 4) . This implies that the accumulation of serum remnant lipoproteins occurs in the high-TG type subjects. More over, the high-TG type subjects had a significant reduc tion in serum RLP-C level during the G-hesperidin administration period (Fig. 4) , suggesting that G-hes peridin decreases the accumulation of serum remnant lipoproteins. Therefore, there is a possibility that G-hes peridin improves VLDL metabolic abnormality in the high-TG type. This effect is likely to be elicited by the suppression of VLDL synthesis or the augmentation of VLDL catabolism.
The possibility mentioned above was supported by the results of serum apolipoprotein analyses. We observed that elevated values of serum apo C-II, apo C III and apo E occurred in the high-TG type and that these apolipoprotein levels were significantly reduced by G-hesperidin administration (Fig. 6 ). Apo C-II, apo C-III and apo E are bound to VLDL and remnant lipoproteins, respectively (33-35); and furthermore, their high val ues reflect the accumulation of serum VLDL and rem nant lipoproteins.
Our results indicate that the accumu lation of serum VLDL and remnant lipoproteins occurs in the high-TG type and that these serum levels are reduced by G-hesperidin administration.
The effect of G-hesperidin on VLDL metabolic abnor mality was further clarified by the PAGE analysis of serum lipoproteins. When serum lipoprotein composi tion of respective phenotypes was investigated using PAGE analysis, the initial VLDL/LDL ratio of the high TG type was remarkably higher than those of the other phenotypes (Figs. 7 and 8 ). This result indicates that the rate of VLDL accumulation in serum is elevated in the high-TG type as compared with the other pheno types, probably reflecting an excess of VLDL synthesis or a deficiency of VLDL catabolism. In the high-TG type subjects with such VLDL metabolic abnormality, G-hes peridin significantly lowered their VLDL/LDL ratios ( Figs. 7 and 8 ). This observation provides proof that G hesperidin improves the metabolic abnormality in the high-TG type through the suppression of VLDL synthe sis or the augmentation of VLDL catabolism.
It is not clear whether G-hesperidin acts on the syn thetic process or the catabolic process of VLDL. How ever, we observed that serum apo B level was signifi cantly reduced during the administration period (Fig.  6 ). It is known that apo B forms VLDL by complexing with TG and cholesteryl ester in hepatocytes and is secreted from the liver (36) (37) (38) (39) . On the basis of this finding, serum apo B level is regarded as an index of hepatic VLDL synthesis. Thus, our observation may be possibly interpreted to mean that G-hesperidin sup presses VLDL synthesis in the liver. In addition, we recently found that G-hesperidin significantly decreased apo B secretion in cultured human hepatocytes (unpub lished data). Moreover, hesperetin, which is released from hesperidin through deglycosylation by bacteria in the gastrointestinal tract, has been reported to inhibit apo B secretion in cultured human hepatocytes (40, 41) . These findings strongly suggest a possibility that G hesperidin suppresses hepatic VLDL synthesis. Hence, in vitro experiments monitoring apo B secretion from hepatocytes are in progress in our laboratory to eluci date the influence of G-hesperidin on hepatic VLDL syn thesis.
Interestingly, it was observed that the initial serum AST, ALT and y-GT values of the high-TG type tended to be higher than those of the other phenotypes and that these serum levels were drastically lowered during the administration period (Fig. 9) . From these results, G-hesperidin is suggested to repair the abnormal hepatic functions of the high-TG type subjects. Addi tionally, these observations support that G-hesperidin exhibits its effects in the liver. As mentioned above, VLDL is synthesized via the assembly of TG, cholesteryl ester and apo B in the liver and secreted into blood cir culation (36) (37) (38) (39) . Therefore, it seems likely that G-hes peridin acts on the process of VLDL synthesis in the liver. In order to further clarify this, we recently started the investigations focused on the process of VLDL assembly in the liver. On the other hand, it has been reported that hesperetin reduces the hepatic TG accu mulation in orotic acid-fed rats through the inhibition of a TG synthetic enzyme, phosphatidic acid phospho hydrolase (42) . Thus, G-hesperidin may also exhibit similar effect in the liver.
Although we previously observed that serum TC and LDL-C levels were not altered by 6-wk administration of G-hesperidin (10), these serum levels significantly decreased after week 16 of the administration period in the present study (Fig. 5) . Since the decrease of these serum cholesterol levels was detected in all phenotypes (Fig. 5) , this effect was speculated to be caused indepen dently of the mechanisms by which G-hesperidin low ered serum TG level. It has been reported that hesperi din lowers serum TC and LDL-C levels in rats and that the effect is attributed to suuuuressing cholesterol syn thesis by the inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (43, 44) . Such a mechanism was considered to cause G-hesperidin to lower serum TC and LDL-C levels of the subjects in this study. However, it seems likely that long-term adminis tration is required to lower these serum cholesterol lev els. Human HMG-CoA reductase may have a low sus ceptibility to G-hesperidin, compared to that of rats.
In contrast, the serum HDL-C level showed no obvi ous change from G-hesperidin administration (Fig. 5) as described previously (10). Moreover, the serum level of apo A-I, bound to HDL, was also unchanged during the administration period (Fig. 6) . HDL is recognized to play a critical role in the process of VLDL catabolism because it removes TG from VLDL via cholesteryl ester transfer protein (CETP) (45, 46) . Nevertheless, on the basis of our observations, it is unlikely that G-hesperidin enhances VLDL catabolism through affecting the TG removal by CETP.
Recent studies have shown that hypertriglyceridemic patients possess small dense LDL with high frequency (14, 15) and that this abnormal LDL is closely involved in coronary artery disease (16, 17) . In addition, it has been presumed that small dense LDL formation, which remains unclear, can be attributed to the accumulation of serum TG-rich lipoproteins by VLDL metabolic abnor mality (47) (48) (49) . As expected, LDL particle size and serum level of TG or RLP-C tended to be inversely corre lated in the preset study (Table 1, Fig. 10) . Especially, the initial LDL particle size of the high-TG type was smaller than those of the other phenotypes, suggesting the presence of small dense LDL (Figs. 8 and 10 ). In this phenotype, G-hesperidin administration led to an increase in LDL particle size (Figs. 8 and 10 ). This result is in good agreement with that reported previously (10) . From these findings, it is suggested that G-hesperi din improves VLDL metabolic abnormality and results in the reduction of small dense LDL formation.
The active form of G-hesperidin in vivo is considered to be hesperetin. In fact, Chiba et al, have reported that hesperetin conjugated with glucuronic acid is detected in the serum of mice fed G-hesperidin (50) . Further more, we have observed that serum concentrations of hesperetin glucuronides in rats administered G-hesperi din are markedly higher than those in rats administered hesperidin (6) . This observation implies that G-hesperi din is absorbed more efficiently than hesperidin due to its high water solubility. Based on such a beneficial property, G-hesperidin can be assumed to exhibit its activity effectively in the body.
In conclusion, the present study has indicated that a 24-wk administration of G-hesperidin preferentially lowers serum TG level in hypertriglyceridemic subjects and that this effect is possibly due to the repair of VLDL metabolic abnormality. This action also participates in the suppression of small dense LDL formation, suggest ing a potential for preventing atherosclerosis progres sion.
